Saneca Pharmaceuticals's operating cash flow stood at EUR -0.519 mil in 2019, up 0% when compared to the previous year. Historically, between 2019 - 2019, the firm’s operating cash flow reached a high of EUR -0.519 mil in 2019 and a low of EUR -0.519 mil in 2019.
Saneca Pharmaceuticals's total investments stood at EUR -3.69 mil and accounted for 6.42% of sales in 2019. This is compared to an average of 6.42% as seen over the last five years.
Cash from financing amounted to EUR 2.11 mil, so the company generated EUR -2.10 mil net cash in 2019.
At the end of 2019, the company had a net debt of EUR 8.68 mil, or -5.20x of EBITDA and 35.7% of equity. Net working capital amounted to EUR 20.4 mil, or 35.4% of sales. Cash conversion cycle is negative and reached days in 2019. This means Saneca Pharmaceuticals generates revenue from customers before it has to pay its suppliers for inventory, among other things.
You can see all the company’s data at Saneca Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
